Tarsus Pharmaceuticals, Inc. Common Stock (TARS) is a publicly traded Healthcare sector company. As of May 21, 2026, TARS trades at $64.83 with a market cap of $2.70B and a P/E ratio of -56.22. TARS moved +5.71% today. Year to date, TARS is -18.76%; over the trailing twelve months it is +44.36%. Its 52-week range spans $31.36 to $85.25. Analyst consensus is strong buy with an average price target of $95.17. Rallies surfaces TARS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TARS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $64.83 |
| Market Cap | $2.70B |
| P/E Ratio | -56.22 |
| EPS | $-1.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $85.25 |
| 52-Week Low | $31.36 |
| Volume | 15 |
| Avg Volume | 0 |
| Revenue (TTM) | $535.08M |
| Net Income | $-48.27M |
| Gross Margin | 0.00% |
8 analysts cover TARS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.17.